Stock Taper
SCREENER
COMPARE ANY 2 STOCKS
Pricing
Log In
SIGN UP
EARNINGS CALL ARCHIVE
1 CALL ON FILE
DNLI
— Denali Therapeutics Inc.
NASDAQ
FULL STOCK PAGE →
Q2 2026 Earnings Call Summary
AUG 6, 2026
REVENUE
$3.6M
NET MARGIN
-3539.2%
EPS
-$0.68
+1.4%
FREE CASH FLOW
-$97.8M
+26.8%
No summary has been written for this call yet.
← NEWER CALL
CALL 1 OF 1
OLDER CALL →